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Abstract
Background: Heparanase facilitates the invasion and metastasis of cancer cells, and is over-expressed in many
kinds of malignancies. Our studies indicated that heparanase was frequently expressed in advanced gastric cancers.
The aim of this study is to determine whether silencing of heparanase expression can abolish the malignant
characteristics of gastric cancer cells.
Methods: Three heparanase-specific small interfering RNA (siRNAs) were designed, synthesized, and transfected
into cultured gastric cancer cell line SGC-7901. Heparanase expression was measured by RT-PCR, real-time
quantitative PCR and Western blot. Cell proliferation was detected by MTT colorimetry and colony formation assay.
The in vitro invasion and metastasis of cancer cells were measured by cell adhesion assay, scratch assay and
matrigel invasion assay. The angiogenesis capabilities of cancer cells were measured by tube formation of
endothelial cells.
Results: Transfection of siRNA against 1496-1514 bp of encoding regions resulted in reduced expression of
heparanase, which started at 24 hrs and lasted for 120 hrs post-transfection. The siRNA-mediated silencing of
heparanase suppressed the cellular proliferation of SGC-7901 cells. In addition, the in vitro invasion and metastasis
of cancer cells were attenuated after knock-down of heparanase. Moreover, transfection of heparanase-specific
siRNA attenuated the in vitro angiogenesis of cancer cells in a dose-dependent manner.
Conclusions: These results demonstrated that gene silencing of heparanase can efficiently abolish the proliferation,
invasion, metastasis and angiogenesis of human gastric cancer cells in vitro, suggesting that heparanase-specific
siRNA is of potential values as a novel therapeutic agent for human gastric cancer.
Background
Gastric cancer is one of the most common cancer types
in the world, although its incidence has gradually
decreased in recent years in many countries [1]. Inva-
sion and metastasis of cancer cells remains the main
cause of gastric cancer-related death [2]. It is well
known that the basement membrane (BM) and extracel-
lular matrix (ECM) play a barrier to prevent tumor cells
from invasion and metastasis [3]. Specific enzymes pro-
duced by cancer cells and activated by certain signals,
such as matrix metalloproteinases (MMPs) and
urokinase-type plasminogen activator (uPA), have been
reported to degrade BM and ECM, and are associated
with progression of gastric cancer [4-7]. A better knowl-
edge of changes in gene expression during invasion and
metastasis may lead to improvements in the treatment
of advanced gastric cancer.
Heparan sulfate (HS) and heparin sulfate proteoglycans
(HSPGs), the important structural components of ECM
and external surface of cell membranes, play a major role
in cell-cell and cell-ECM interactions [8]. Previous
reports have shown that heparanase (HPA), an endo-h-
D-glucuronidase, has the ability to cleave the heparan
sulfate chain of HSPGs, and is one of the key enzymes
involved in the invasion and metastasis of malignant
tumors [9]. Under normal physiological conditions, HPA
expression is detectable in endothelial cells, smooth
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platelets, neutrophils, and activated T lymphocytes [10].
However, HPA expression is up-regulated in many
tumor cells including esophageal carcinoma, pancreatic
carcinoma, melanoma, bladder cancer, and prostate can-
cer [11-15]. It has been established that a significant cor-
relation of HPA over-expression is coupled with
increased metastatic potential and decreased survival
rates of cancer [16]. These studies suggest that HPA is
correlative with invasion and metastasis of cancer cells,
and served as an important target of cancer therapy.
Previous studies indicate that the expression of HPA
was frequently observed in advanced gastric cancers
[17,18]. The frequency was significantly correlated with
histopathological parameters reflecting invasive and
metastatic potentials and prognosis of gastric cancers
[17,18]. Our studies also demonstrated the over-expres-
sion of HPA protein in advanced gastric cancer (data
not shown). However, it still remains largely unknown
whether inhibiting HPA expression can abolish the inva-
sion and metastasis of gastric cancer cells. Due to the
non-specific activities of current HPA inhibitors and the
great difficulties in identifying efficient inhibitors
[19-22], genetic approaches targeting HPA have been
regarded as a promising alternative [23]. RNA interfer-
ence (RNAi) is a posttranscriptional mechanism of gene
silencing through chromatin remodeling, inhibition of
protein translation or direct mRNA degradation [24].
Chemically synthetic small interfering RNA (siRNA) is
currently being evaluated not only as an extremely
powerful instrument for functional genomic analyses,
but also as a potentially useful method to develop highly
specific gene-silencing therapeutics [25]. In this study,
we designed HPA-specific siRNAs and evaluated their
gene silencing effects in cultured gastric cancer cells.
We demonstrated that silencing of HPA expression atte-
nuated the in vitro invasion, metastasis and angiogenesis
capabilities of gastric cancer cells.
Methods
Cell culture
Human gastric cancer cell line SGC-7901 and endothe-
lial cell line HUVEC were purchased from American
Type Culture Collection (ATCC) and grown in
RPMI1640 medium (Life Technologies, Inc., Gaithers-
burg, MD) supplemented with 10% fetal bovine serum
(FBS, Life Technologies, Inc.), penicillin (100 U/ml)
and streptomycin (100 μg/ml). Cells were maintained at
37°C in a humidified atmosphere of 5% CO2.
Heparanase-specific siRNA and transfection
For RNA interference, three 21-nucleotide siRNA
duplexes targeting different encoding regions of HPA
(GenBank accession No. AF165154) were designed and
chemically synthesized (Ribobio Co. Ltd, GuangZhou,
China). The secondary structures of target mRNA were
predicted by RNAstructure 3.7 software [26]. The
nucleotide sequences were as follows: siH1 (1088-1106
bp), 5’-UUAUGUGGCUGGAUAAAUUtt-3’ (sense), and
5’-AAUUUAUCCAGCCACAUAAtt-3’ (antisense); siH2
(1267-1285 bp), 5’-GUGCAAGGUUCAAAGAGAAtt-3’
(sense), and 5’-UUCUCUUUGAACCUUGCACtt-3’
(antisense); siH3 (1496-1514 bp), 5’-CUCUAAAGA
UGGUGGAUGAtt-3’ (sense), and 5’-UCAUCCACCAU-
CUUUAGAGtt-3’ (antisense). The sequences 5’-AGC
AUCGUACGUAGGCCAGtt-3’ (sense), and 5’-CUGGC
CUACGUACGAUG CUtt-3’ (antisense) were used as a
scrambled siRNA control (mock). The siRNAs were
transfected into culture cells with Genesilencer Trans-
fection Reagent (Genlantis, San Diego, CA), according
to the manufacturer’s instructions.
Real-time quantitative PCR
Total RNA was isolated with RNeasy Mini Kit (Qiagen
Inc., Valencia, CA). The reverse transcription reactions
were conducted with Transcriptor First Strand cDNA
Synthesis Kit (Roche, Indianapolis, IN). The PCR pri-
mers were designed by Premier Primer 5.0 software as
the following: for human HPA 5’-GAATGGACG-
GACTGCTAC-3’ and 5’-CCAAAGAATACTTGCC
TCA-3’ amplifying a 261-bp fragment; for human GA
PDH 5’-AGAAGGCTGGGGCTCATT TG-3’ and 5’-AG
GGGCCATCCACAGTCTTC-3’ amplifying a 258-bp
fragment. Real-time PCR with SYBR Green PCR Master
Mix (Applied Biosystems, Foster City, CA) was per-
formed using ABI Prism 7700 Sequence Detector
(Applied Biosystems). The fluorescent signals were col-
lected during extension phase, Ct values of the sample
were calculated, and HPA transcript levels were ana-
lyzed by 2
-ΔΔCt method.
Western blot
Cellular protein was extracted with 1× cell lysis buffer
(Promega, Madison, WI). Protein (50 μg) from each sam-
ple was subjected to 4-20% pre-cast polyacrylamide gel
(Bio-Rad, Hercules, CA) electrophoresis and transferred to
nitrocellulose membranes (Bio-Rad). For HPA (InSight
Company, Rehovot, Israel) and GAPDH (Santa Cruz Bio-
technology, Santa Cruz, CA) detection, the primary anti-
body dilutions were 1:500 and 1:1000, respectively,
followed by 1:3000 dilution of goat anti-rabbit HRP-
labeled antibody (Bio-Rad). ECL substrate kit (Amersham,
Piscataway, NJ) was used for the chemiluminscent detec-
tion of signals with autoradiography film (Amersham).
Measurement of cell viability
Forty-eight hrs post-transfection, cell viability was moni-
tored by the 2-(4, 5-dimethyltriazol-2-yl)-2,5-diphenyl
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Page 2 of 11tetrazolium bromide (MTT, Sigma) colorimetric assay.
Briefly, 20 μl of MTT (5 mg/ml) was added to each
well. After 4 hrs of incubation at 37°C, the cell superna-
tants were discarded, MTT crystals were dissolved with
DMSO and the absorbance measured at 570 nm. Per-
cent viability was defined as the relative absorbance of
transfected versus untransfected control cells. All experi-
ments were done with 6-8 wells per experiment and
repeated at least three times.
Colony formation assay
Forty-eight hrs post-transfection, the cells were seeded
at a density of 300/ml on 35-mm dishes. Colonies were
allowed to grow for 10-14 days. The medium was dis-
carded and each well was washed twice with phosphate
buffered saline (PBS) carefully. The cells were fixed in
methanol for 15 min, and then stained with crystal vio-
let for 20 min. Finally, positive colony formation (more
than 50 cells/colony) was counted. The survival fraction
for cells was expressed as the ratio of plating efficiency
of transfected cells to that of untransfected control cells.
Cell adhesion assay
Forty-eight hrs post-transfection, 2 × 10
4 cells were
inoculated into each well of 96-well plates that were
precoated with 100 μlo f2 0μg/ml matrigel (BD Bios-
ciences, Franklin Lakes, NJ), and incubated at 37°C in
serum-free complete medium (pH 7.2) for 2 hrs. After
incubation, the wells were washed three times with PBS
and the remaining cells were fixed in 4% paraformalde-
hyde for 20 min at room temperature. The cells were
stained with 0.1% crystal violet and washed three times
with PBS to remove free dye. After extraction with 10%
acetic acid, absorbance of the samples was measured at
570 nm. 0%, 20%, 50% and 100% of inoculated cells
were directly fixed in 4% paraformaldehyde 2 hrs after
inoculation.
Scratch migration assay
SGC-7901 cells were transfected in 24-well plate with
siRNAs. Forty-eight hrs post-transfection, the cells were
scraped with the fine end of 1-ml pipette tips (time 0).
Plates were washed twice with PBS to remove detached
cells, and incubated with the complete growth medium.
Cell migration into the wounded empty space was fol-
lowed after 24 hrs and photographed.
Matrigel invasion assay
The Boyden chamber technique (transwell analysis) was
performed. Briefly, the 8-μmp o r es i z ef i l t e r sw e r e
coated with 100 μl of 1 mg/ml matrigel (dissolved in
serum-free RPMI1640 medium). 600 μlo fR P M I 1 6 4 0
medium containing 10% FBS was added to the lower
chambers. Forty-eight hrs post-transfection,
homogeneous single cell suspensions (1 × 10
5 cells/well)
were added to the upper chambers and allowed to
invade for 24 hrs at 37°C in a CO2 incubator. Cells
remaining attached to the upper surface of the filters
were carefully removed with cotton swabs. Migrated
cells were stained with 0.1% crystal violet for 10 min at
room temperature and examined by light microscopy.
Quantification of migrated cells was performed accord-
ing to published criteria [27].
Tube formation assay
Fifty microliters of growth factor-reduced matrigel was
polymerized on 96-well plates. HUVECs were serum
starved in RPMI1640 medium for 2 hrs. The cells were
suspended in RPMI1640 medium preconditioned with
siRNA-transfected SGC-7901 cells, added to the matri-
gel-coated wells at the density of 5 × 10
4 cells/well, and
incubated at 37°C for 18 hrs. Tube formation was visua-
lized using a Leitz inverted microscope equipped with a
Sony color digital DXC-S500 camera. Quantification of
antiangiogenic activity was calculated by measuring the
length of tube walls formed between discrete endothelial
cells in each well relative to the control.
Statistical analysis
Unless otherwise stated, all data were shown as mean ±
standard error of the mean (SEM). Statistical signifi-
cance (P < 0.05) was determined by t test or analysis of
variance (ANOVA) followed by assessment of differ-
ences using SPSS 12.0 software (SPSS Inc., Chicago, IL).
Results
siRNA suppressed the HPA expression
in gastric cancer cells
As shown in Figure 1A, three siRNA duplexes targeting
different encoding regions of human HPA mRNA,
named as siH1, siH2 and siH3, were designed and
synthesized. Their siRNA sequences and the secondary
structures of target mRNA were shown in Figure 1B.
Under the mediation of Genesilencer, siRNAs were trans-
fected into gastric cancer cell line SGC-7901. The mRNA
and protein expression of HPA were examined by RT-
PCR, real-time quantitative PCR and Western blot. As
shown in Figure 2A, high HPA mRNA and protein levels
were detected in the parental cells, and the scrambled
siRNA control (mock, 100 nmol/L) did not affect the
expression levels of HPA. The siH3 (100 nmol/L) exerted
the most efficiency in suppressing the HPA expression,
and siH1 (100 nmol/L) inhibited the HPA expression to a
lesser extent (Figure 2A). However, transfection of siH2
(100 nmol/L) slightly influenced the expression of HPA
in SGC-7901 cells (Figure 2A). In addition, the siH3-
induced suppression of HPA expression of SGC-7901
cells started at 24 hrs, and lasted for 120 hrs (Figure 2B).
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Page 3 of 11Figure 1 Design of siRNA targeting different encoding regions of heparanase. (A) Taken the heparanase mRNA (GenBank accession No.
AF165154) as a target, three siRNA duplexes were designed and named as siH1, siH2, and siH3. Their corresponding targets located at 1088-
1106 bp, 1267-1285 bp, and 1496-1514 bp of the encoding regions of heparanase mRNA. (B) Prediction of the secondary structures of siRNA
targets was performed via RNAstructure 3.7 software. The siH1 recognized a region with three loops and two stems, while siH2 recognized a
region with one loop and two stems. The target region of siH3 was sequestered intentionally in a stable stem structure. The red line indicated
the target region of siRNA.
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Page 4 of 11Figure 2 siRNA suppressed the heparanase expression in gastric cancer cells. Confluent gastric cancer SGC-7901 cells were seeded into 6-
well plates, and transfected with different heparanase-specific siRNAs (siH1, siH2 and siH3) or scrambled siRNA (mock). The untransfected cells
served as a control (No). The mRNA and protein expression of heparanase were examined by RT-PCR, real-time quantitative PCR and Western
blot. (A) Forty-eight hrs post-transfection, siH3 (100 nmol/L) exerted the most efficiency in suppressing the heparanase expression, and siH1 (100
nmol/L) inhibited the heparanase expression to a lesser extent. However, transfection of siH2 (100 nmol/L) slightly influence the expression of
heparanase in SGC-7901 cells. (B) The siH3 (100 nmol/L)-induced suppression of heparanase expression of SGC-7901 cells started at 24 hrs, and
lasted for 120 hrs. Of note, the heparanase mRNA levels, but not the heparanase protein levels, were partially restored at 120 hrs post-
transfection. (C) Transfection of different concentrations (10 nmol/L, 50 nmol/L and 100 nmol/L) of siH3 into SGC-7901 cells for 48 hrs, resulted
in decrease of heparanase expression in a dose-dependent manner. The symbols (* and **) indicates a significant (P < 0.05) and a very
significant (P < 0.01) decrease from mock, respectively. Triplicate experiments were performed with essentially identical results.
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levels, were partially restored at 120 hrs post-transfection
(Figure 2B). Moreover, transfection of different concen-
trations (10 nmol/L, 50 nmol/L and 100 nmol/L) of siH3
into SGC-7901 cells for 48 hrs, resulted in decrease
of HPA expression in a dose-dependent manner
(Figure 2C). These results indicated that the siRNAs,
siH3 and siH1, were efficient in down-regulating the
expression of HPA in gastric cancer cells.
Silencing HPA attenuated the in vitro cell proliferation of
gastric cancer cells
Since previous studies indicate that HPA modulates the
cell proliferation of cancer cells [28], we first examined
the effects of HPA siRNA on cell proliferation of SGC-
7901 cells by MTT colorimetric assay. We found that
transfection of siH3 for 48 hrs attenuated the cell prolif-
eration in a dose-dependent manner, when compared to
the parental cells and mock group (Figure 3A). In addi-
tion, the colony formation assay further revealed
that 48 hrs post-transfection, high concentrations of
siH3 (50 nmo/L and 100 nmol/L), but not low concen-
tration of siH3 (10 nmol/L), attenuated the cell prolif-
eration of cultured SGC-7901 cells (Figure 3B). These
results indicated that siH3 attenuated the in vitro cell
proliferation of gastric cancer cells.
Silencing HPA abolished adhesion, migration and
invasion of gastric cancer cells in vitro
Since HPA plays critical roles in invasion and metasta-
sis of cancer cells [9], and three critical steps are
involved in metastasis, that is adhesion, migration and
invasion [9], we further observed the effects of HPA-
specific siH3 on these characteristics of SGC-7901
cells. In the adhesion assay, 48 hrs post-transfection,
high concentrations of siH3 (50 nmo/L and 100 nmol/
L), but not low concentration of siH3 (10 nmol/L),
reduced the ability of SGC-7901 cells in adhesion to
the precoated matrigel, when compared to parental
cells (Figure 4A). However, the cells transfected with
scrambled siRNA control (mock, 100 nmol/L) had
similar ability in adhesion as parental cells (Figure 4A).
In addition, 48 hrs post-transfection, the cells trans-
fected with siH3 demonstrated an impaired migration
capacity in a dose-dependent manner, when compared
to the parental cells and mock group as evidenced by
scratch migration assay (Figure 4B). Moreover, the
transwell analysis indicated that transfection of siH3
for 48 hrs abolished the invasive capabilities of SGC-
7901 cells in a dose-dependent manner, when com-
pared to the parental cells and mock group (100 nmol/
L) (Figure 4C). These results suggested that HPA-spe-
cific siH3 suppressed the adhesion, invasion and
metastasis of gastric cancer cells in vitro.
Silencing HPA inhibited the in vitro angiogenesis of
gastric cancer cells
Since HPA participates in the angiogenesis of
tumor [29,30], we further investigated the effects of
HPA-specific siH3 on the in vitro angiogenesis capabil-
ities of SGC-7901 cells. As shown in Figure 5, extensive
tube formation of endothelial cells was observed in non-
transfection and mock (100 nmol/L) groups. However,
when the endothelial cells were treated by the medium
preconditioned with siH3-transfected SGC-7901 cells,
the tube formation was dose-dependently suppressed
(Figure 5). These results indicate that transfection of
siH3 remarkably decreased the angiogenesis of gastric
cancer cells in vitro.
Discussion
Degradation of basement membrane (BM) and extracel-
lular matrix (ECM) comprises an initial and essential
step for cancer cells to invade surrounding tissue and
metastasize to distant organs [31]. Both the BM and
ECM contain heparan sulfite (HS) and heparan sulfate
proteoglycans (HSPGs) as major structural components,
which are substrates for heparanase (HPA) [9]. Human
HPA gene is located on chromosome 4q21.3, and its
cDNA contains an open reading frame of 1629-bp that
encodes for a 61.2 kDa polypeptide of 543 amino acids
[32-34]. Preferential expression of HPA mRNA and pro-
tein in tumors is evident in tissue specimens derived
from oral squamous cell carcinoma [35], hepatocellular
carcinoma [36], and carcinomas of prostate [15], bladder
[14], and pancreas [37]. It has been reported that HPA
correlated with the metastatic potential of mouse B16
melanoma and Eb lymphoma cells [38]. Subcutaneous
inoculation of non-metastatic Eb lymphoma cells engi-
neered to over-express HPA resulted in a significant
decease in survival time of the mice due to a massive
liver infiltration [32]. These findings support the correla-
tion between HPA expression and the metastatic capa-
city of cancer cells.
Since HPA plays an important role in the invasion and
metastasis of cancer cells, many studies focus on the
development of HPA inhibitors [23]. With the availabil-
ity of recombinant HPA and the establishment of high-
throughput screening methods, a variety of inhibitory
molecules have been developed, including neutralizing
antibodies, peptides, small molecules, modified non-
anticoagulant species of heparin [23], as well as several
other polyanionic molecules, such as laminaran sulfate,
suramin and PI-88 [20,39,40]. These inhibitors that
decrease HPA expression in cancer cells significantly
reduce their metastatic properties, signifying the impor-
tance of HPA in cancer cell spread [20,23,39,40]. How-
ever, because of the multiple biologic activities of these
compounds, the mechanism of their antitumor activity
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Page 6 of 11Figure 3 Silencing heparanase attenuated the in vitro cell proliferation of gastric cancer cells. Confluent SGC-7901 cells were seeded into
96-well plates, and transfected with different concentrations (10 nmol/L, 50 nmol/L, and 100 nmol/L) of siH3 or scrambled siRNA (mock, 100
nmol/L). The untransfected cells served as a control (No). (A) Forty-eight hours post-transfection, MTT colorimetry was performed to assay the
cell proliferation. The results indicated that high concentrations of siH3 (50 nmo/L and 100 nmol/L), but not low concentration of siH3 (10 nmol/
L) or scrambled siRNA (mock, 100 nmol/L), attenuated the proliferation of SGC-7901 cells, when compared to the parental cells. (B) In colony
formation assay, 48 hrs post-transfection, the cells were seeded at a density of 300/ml on 35-mm dishes. Colonies were allowed to grow for 10-
14 days. Positive colony formation (more than 50 cells/colony) was counted. The results indicated that high concentrations of siH3 (50 nmo/L
and 100 nmol/L), but not low concentration of siH3 (10 nmol/L) or scrambled siRNA (mock, 100 nmol/L), attenuated the cellular colony
formation rates of cultured SGC-7901 cells. The symbols (* and **) indicates a significant (P < 0.05) and a very significant (P < 0.01) decrease
from mock, respectively. Triplicate experiments were performed with essentially identical results.
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Page 7 of 11Figure 4 Silencing heparanase abolished the adhesion, migration and invasion of gastric cancer cells in vitro. Confluent SGC-7901 cells
were seeded into 96-well or 24-well plates, and transfected with different concentrations (10 nmol/L, 50 nmol/L, and 100 nmol/L) of siH3 or
scrambled siRNA (mock, 100 nmol/L). The untransfected cells served as a control (No). (A) In the adhesion assay, 48 hrs post-transfection, 2 × 10
4
cells were inoculated into each matrigel-coated well of 96-well plates for 2 hrs, and washed three times with PBS. The results indicated that
transfection of high concentrations of siH3 (50 nmo/L and 100 nmol/L), but not low concentration of siH3 (10 nmol/L) or mock, reduced the
adhesion of SGC-7901 cells to the matrigel. (B) In scratch migration assay, 48 hrs post-transfection, the cells were scraped with 1-ml pipette tips
(time 0). Cell migration into the wounded empty space was followed after 24 hrs and photographed. The results indicated that transfection of
siH3 impaired the cellular migration in a dose-dependent manner. (C) In transwell analysis, 48 hrs post-transfection, homogeneous single cell
suspensions (1 × 10
5 cells/well) were added to the upper chambers and allowed to invade for 24 hrs. Migrated cells were stained with 0.1%
crystal violet and examined by light microscopy. The results indicated that transfection of siH3 abolished the invasion of SGC-7901 cells in a
dose-dependent manner. The symbols (* and **) indicates a significant (P < 0.05) and a very significant (P < 0.01) decrease from mock,
respectively. Triplicate experiments were performed with essentially identical results.
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forward. Moreover, the pleiotropic interactions of
these compounds with the ECM and the cell surface
might produce nonspecific and undesirable effects
[20,23,39,40]. Thus, novel approaches are needed to
inhibit the role of HPA in cancer progression [23].
Recent report indicated that short hairpin RNA
(shRNA) targeting mouse HPA reduced the metastatic
potential of B16-BL6 mouse melanoma cells [38]. Mice
inoculated with Eb lymphoma cells transfected with
anti-HPA ribozyme exhibited a marked decrease in liver
metastasis and survived significantly longer [38]. Current
selection of efficient siRNAs relies mainly on the analy-
sis of sequence elements that mediate efficient incor-
poration into the RNA-induced silencing complex
(RISC) [41,42]. However, several studies have suggested
the importance of target secondary structure and acces-
sibility based on computational modeling of target struc-
ture [43-45]. In this study, we designed three siRNAs
targeting the HPA, named as siH1, siH2 and siH3,
according to the guidelines for siRNA design [46,47]. It
is well established that once siRNAs are transfected into
cells, the guide (antisense) strand of siRNA duplex is
incorporated into the RISC, which identifies target
Figure 5 Silencing heparanase inhibited the in vitro angiogenesis of gastric cancer cells. Fifty microliters of growth factor-reduced
matrigel was polymerized on 96-well plates. HUVECs were serum starved in RPMI1640 medium for 2 hrs, suspended in RPMI1640 medium
preconditioned with siH3-transfected SGC-7901 cells, added to the matrigel-coated wells at the density of 5 × 10
4 cells/well, and incubated at
37°C for 18 hrs. Tube formation was visualized and calculated by measuring the length of tube walls formed between discrete endothelial cells
in each well. Extensive tube formation of endothelial cells was observed in non-transfection (No) and scrambled siRNA (mock, 100 nmol/L)
groups. However, when the endothelial cells were treated by the medium preconditioned with siH3-transfected SGC-7901 cells, the tube
formation was dose-dependently suppressed. The symbols (* and **) indicates a significant (P < 0.05) and a very significant (P < 0.01) decrease
from mock, respectively. Triplicate experiments were performed with essentially identical results.
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[41,42]. An endoribonuclease then cleaves target mRNA,
resulting in knock-down of gene expression [41,42]. We
found that siH3 was most potent in suppressing the
HPA expression in gastric cancer cells even through its
predicted secondary structure of target mRNA was
sequestered intentionally in a stable stem structure.
These results were consistent with previous findings
that large variation in the efficiency of siRNAs for differ-
ent sites on the same target is commonly observed [48].
Thus, it is usually recommended to test several siRNAs
in order to achieve the most potent one.
The relationship between HPA and cell proliferation is
not established yet [49]. In this study, we found that
down-regulation of HPA inhibited the proliferation of
SGC-7901 cells in vitro. In addition, the biologic and
therapeutic relevance of the HPA-silencing approach
was validated using the cell adhesion assay, scratch
migration assay, and matrigel assay. We found that the
invasion and metastasis of gastric cancer cells in vitro
were attenuated by HPA-specific siRNA. Apart from its
involvement in invasion and metastasis of cancer, HPA
is tightly involved in angiogenesis, primarily by means of
releasing heparin-binding angiogenic factors sequestered
by HS in BM and ECM, such as basic fibroblast growth
factor, vascular endothelial growth factor, keratinocyte
growth factor and hepatocyte growth factor [29,30]. A
critical early event in the angiogenic process is degrada-
tion of the subendothelial BM, followed by endothelial
cell migration toward the angiogenic stimulus [29,30].
By releasing HS-bound angiogenic growth factors from
the ECM, active HPA may indirectly facilitate EC migra-
tion and proliferation [29,30]. In this study, we found
that the angiogenesis of gastric cancer cells in vitro was
suppressed by HPA-specific siRNA. However, we noted
that even after knock-down of HPA, the gastric cancer
cells still possessed the capabilities of invasion, metasta-
sis, and angiogenesis. We believe that other factors,
such as uPA and MMPs [4-7], also influence these char-
acteristics of gastric cancer, which warrants our further
investigation. The data described here indicate the
potential application of HPA-specific siRNA in the treat-
ment of gastric cancer. Since previous studies indicate
that the intratumoral injection of siRNAs is a feasible
and convenient method for preliminary evaluation of
siRNA effect in animal models [50], further in vivo
study is warranted to better evaluate the efficiency of
HPA-specific siRNAs on the invasion and metastasis of
gastric cancer.
Conclusion
I ns u m m a r y ,w eh a v ed e m o n s t rated that silencing the
expression of human HPA can efficiently inhibit the
invasion, metastasis and angiogenesis of human gastric
cancer cells. It is likely that the inhibition of HPA
expression possibly depresses the degrading of ECM and
BM, thus inhibiting the invasion and metastasis of gas-
tric cancer. Therefore, our study suggests that HPA-spe-
cific siRNAs may be of potential values as novel
therapeutic agents for human gastric cancer.
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